Biostate Ai
-67%
est. 2Y upside i
Rank
#3461
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: LowAt a $100M entry valuation, the expected equity upside over 2 years is -67.2% under conservative growth assumptions.
Last updated: July 3, 2026
Exit multiple holds at 50x due to successful IPO window or category leadership. Projected revenue $1.92M yields exit value $96M, well below entry valuation. With 20% dilution, upside -24%.
Exit multiple converges to public comp range of 30x. Exit value $57.6M. After 20% dilution, upside -62.4%.
Exit multiple compresses to 20x due to competitive pressure from Illumina and Google DeepMind. Exit value $38.4M, still above total funding $21.46M so common stock recovers partial value. With 20% dilution, upside -81.6%.
Preference Stack Risk
moderateFunding Intensity
379800%Total funding $21.46M vs entry valuation $100M gives 21.5% preference overhang, but bear case exit still above preference threshold.
Dilution Risk
highHigh burn rate and early stage suggest likely raise within 24 months, diluting common shares by 20%.
Secondary Liquidity
noneNo secondary market data; only primary crowdfunding at cap.
Questions to Ask at the Interview
Strategic questions based on Biostate Ai's data — designed to show you've done your homework.
- 1
“What is the current annual revenue run rate and growth trajectory?”
- 2
“How do you plan to compete against Illumina's scale and Google DeepMind's AI capabilities?”
- 3
“What is the expected timing and valuation for the next funding round?”
Community
Valuation Sentiment
Our model estimates -67% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.